Where Akebia Therapeutics Stands With Analysts
Benzinga Insights 8 months ago
Analyst Ratings
In the preceding three months, 5 analysts have released ratings for Akebia Therapeutics (NASDAQ:AKBA), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Akebia Therapeutics, presenting an average target of $5.0, a high estimate of $6.00, and a low estimate of $4.00. This current average has decreased by 10.71% from the previous average price target of $5.60.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we gain insights into how financial experts perceive Akebia Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Julian Harrison | BTIG | Lowers | Buy | $4.00 | $5.00 |
| Allison Bratzel | Piper Sandler | Lowers | Overweight | $4.00 | $6.00 |
| Matthew Caufield | HC Wainwright & Co. | Maintains | Buy | $6.00 | $6.00 |
| Julian Harrison | BTIG | Maintains | Buy | $5.00 | $5.00 |
| Matthew Caufield | HC Wainwright & Co. | Maintains | Buy | $6.00 | $6.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Akebia Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Akebia Therapeutics compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Akebia Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
To gain a panoramic view of Akebia Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Akebia Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Akebia Therapeutics
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Akebia Therapeutics's Economic Impact: An Analysis
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Akebia Therapeutics displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 57.01%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Akebia Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.92%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Akebia Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.15%, the company showcases effective utilization of assets.
Debt Management: Akebia Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 1.26. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.